Domestic PD-1 growth rate is amazing, the first half of sales close to the o drug year- through.

Pharmaceutical Network Industry Dynamics, Cinda Bio announced its second quarter results, Dabershu (Cindilly sLR Injection) in the first and second quarters of revenue of 400 million and 500 million yuan, the first half of this year the product sales have been close to the full year of 2019 1 billion yuan, but also close to O Drug 2019 China sales, domestic PD-1 growth rate is really amazing.
it is understood that Daberschu is an innovative PD-1 inhibitor developed by Cinda Bio and Lilly, which was officially approved by the State Drug Administration on December 24, 2018 for the treatment of recurrent or refractory classic Hodgkin lymphoma after at least second-line system chemotherapy.
in November 2019, Dabershu successfully entered the new version of the Health Care Catalog Category B. In April, Cindilly's second antisomes combined chemotherapy line of treatment for non-squamous non-small cell lung cancer (nsqNSCLC) was declared public, according to the
Insight database.
the indications application is based on a randomized, double-blind, Phase III controlled clinical study (ORIENT-11) - Daberschu (Cindilly Monox injection) or placebo combined force bite (injection of permeyceramita dodium) and platinum for the absence of EGFR sensitive mutations Or the alK gene re-emission of advanced or recurrent non-squamous non-small cell lung cancer first-line treatment;
currently, a total of 23 clinical trials related to Sindili sebutad are under way, including the combination of belavbead singtag and Ipmy monoto-resin.
the PD-1 market is huge, and six PD-1 products have been approved and commercialized.
the industry believes that the new market competition is about to come to an out.
In addition to Cindy Singli Mono- antithesis, from the published data, Junshi's PD-1 Q1 sales this year is about 172 million yuan, 2019 sales of 774 million yuan;
Societe Generale expects that China's PD-1/PD-L1 inhibitor market will experience rapid growth with the increasing accessibility of expanding indications and patient education, with a compound growth rate of 133.5 percent from 2018 to 2023.
it is worth noting that in addition to the four pharmaceutical companies that have been listed, there are four on the way to the market, as well as clinical phase 2.
the relevant person in charge of pharmaceutical companies believe that in the next domestic PD-1 battle, not the price, but in the production capacity.
in addition to mass production, the industry consensus also includes the proof of adaptation. On July 21,
, Jiahe Bio announced that its application for a new drug, Geptanolimab, a PD-1 antibody, had been accepted by the State Drug Administration for the treatment of peripheral T-cell lymphoma (PTCL).
it is understood that at present, Jiahe Bio is in China to carry out a number of clinical trials on Geno monob, involving the indications include peripheral T-cell lymphoma, primary large B-cell lymphoma, cervical cancer, NSCLC, adenosic soft tissue sarcoma and other adaptation evidence.
Hengrui Pharmaceuticals has been approved cHL, liver cancer, esophageal squamous cancer, non-squamous non-small cell lung cancer (joint treatment) 4 adaptation certificates.
, lung and liver cancer are large proof of adaptation, the number of patients accounted for 25% and 21%, respectively.
, NSCLC accounts for about 85 percent of lung cancer, while non-scaly NSCLC accounts for 70 percent of non-small cell lung cancer.
industry veterans believe that lung cancer is expected to account for 40% of the PD-1 market share, estimated market size of 16.829 billion yuan.
second, liver cancer, stomach cancer, esophageal cancer is expected to occupy the PD-1 market share of about 20% to 30%, the total market size is estimated to be 21.978 billion yuan.
.